SARS-CoV-2 (2019-nCoV) Spike RBD, Recombinant, aa319-541, His-Tag
Katalog-Nummer 497077-20ug
Size : 20ug
Marke : US Biological
497077 SARS-CoV-2 (2019-nCoV) Spike RBD, Recombinant, aa319-541, His-Tag
Clone Type
PolyclonalSwiss Prot
P0DTC2Grade
Highly PurifiedAccession #
QHD43416.1Shipping Temp
Blue IceStorage Temp
-20°CAn epidemic of acute respiratory syndrome in humans, which appeared in Wuhan, China in December 2019, was caused by a novel coronavirus (SARS-CoV-2). This disease was named as "Coronavirus Disease 2019" (COVID19). This virus shares highly homological sequence with SARS-CoV, and causes acute, highly lethal pneumonia coronavirus disease 2019 (COVID-19) with clinical symptoms similar to those reported for SARS-CoV and MERSCoV. The genome of this and other emerging pathogenic human CoVs encodes four major structural proteins [spike (S), envelope (E), membrane (M), and nucleocapsid (N)], approximately 16 nonstructural proteins (nsp1–16), and five to eight accessory proteins. Among them, the S protein plays an essential role in viral attachment, fusion, entry, and transmission. It comprises an N-terminal S1 subunit responsible for virus–receptor binding and a C-terminal S2 subunit responsible for virus–cell membrane fusion. S1 is further divided into an N-terminal domain (NTD) and a receptor-binding domain (RBD). SARS-CoV-2 and SARS-CoV bind angiotensinconverting enzyme 2 (ACE2) while MERS-CoV binds dipeptidyl peptidase 4 (DPP4), as receptors on the host cell|expressing ACE2 (e.g., pneumocytes, enterocytes) or DPP4 (e.g., liver or lung cells including Huh-7, MRC-5, and Calu-3). During infection, CoV first binds the host cell through interaction between its S1-RBD and the cell|membrane receptor, triggering conformational changes in the S2 subunit that result in virus fusion and entry into the target cell. ||Recombinant protein corresponding to aa319-341 from SARS-CoV-2 (2019-nCoV) Spike RBD, fused to His-Tag at C-terminal, expressed in HEK293 cells.||Molecular Weight: |~26.3kD||Biological Activity:|Measured by its binding ability in a functional ELISA with Human ACE-2. ||Amino Acid Sequence:|<DGSM>RVQPTE SIVRFPNITN LCPFGEVFNA TRFASVYAWN RKRISNCVAD YSVLYNSASFSTFKCYGVSP TKLNDLCFTN VYADSFVIRG DEVRQIAPGQ TGKIADYNYK LPDDFTGCVI AWNSNNLDSK VGGNYNYLYR LFRKSNLKPF ERDISTEIYQ AGSTPCNGVE GFNCYFPLQS YGFQPTNGVG YQPYRVVVLS FELLHAPATV CGPKKSTNLV KNKCVNF<HHH HHH>||Storage and Stability: |May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 6 months after receipt at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.